25-Year COURAGE Follow-Up Finds No Long-Term Reduction in Death or Heart Attack from Initial Stents in Stable Coronary Disease
An extended follow-up of the COURAGE trial, published in JAMA, shows that adding percutaneous coronary intervention (PCI, including stents) to optimal medical therapy does not significantly lower the combined risk of death or myocardial infarction over up to 25 years in patients with stable coronary artery disease compared with medical therapy alone. Similar long-term results from ISCHEMIA-EXTEND found no survival advantage for an initial invasive strategy. Procedures remain useful for symptom relief and in acute settings.
Key points
- •No significant difference in 25-year death or MI rates: 93.3% PCI vs 91% medical therapy.
- •Median 15-year follow-up of 959 COURAGE veterans; findings consistent with original trial.
- •ISCHEMIA-EXTEND: similar all-cause mortality at 11 years for invasive vs conservative strategies.
Why this is uncovered
Covered in JAMA, specialty cardiology outlets like MedPage and Healio, and science sites such as SciTechDaily, with limited broader mainstream news pickup.
This article was generated automatically from primary sources and has not been reviewed by a human editor. Verify claims before sharing.
A long-term analysis of the landmark COURAGE trial has found that an initial strategy of percutaneous coronary intervention (PCI), which often includes placement of stents to open narrowed coronary arteries, combined with optimal medical therapy does not significantly reduce the risk of death or myocardial infarction (heart attack) compared with optimal medical therapy alone in patients with stable coronary artery disease, even after follow-up extending to 25 years.
The findings were published online in JAMA on November 7, 2026, and presented at the American Heart Association Scientific Sessions. Researchers led by Neel M. Butala, MD, of the University of Colorado Anschutz Medical Campus and Rocky Mountain Regional VA Medical Center, tracked 959 participants from the original COURAGE trial who were enrolled at Veterans Affairs hospitals, using linked health records (CU Anschutz; JAMA).
The original COURAGE trial, reported in 2007, randomized patients with stable coronary artery disease and evidence of ischemia to PCI plus optimal medical therapy or optimal medical therapy alone. It showed no reduction in death or MI at a median of 4.6 years. The new post-hoc extended follow-up had a median duration of 15 years, with some patients observed for as long as 25 years. The estimated 25-year cumulative incidence of the composite of death or MI was 93.3% in the initial PCI group and 91.0% in the medical therapy group (hazard ratio 1.01, 95% CI 0.88-1.15), a difference that was not statistically significant (SciTechDaily; MedPage Today).
Individual components were similarly neutral: estimated 25-year incidence of death was 83.9% with PCI versus 82.2% with medical therapy alone (HR 0.98), and MI rates were 54.6% versus 54.0%. Rates of revascularization during follow-up were also comparable, with nearly half of patients initially assigned to medical therapy never requiring a procedure (Healio; Medscape).
“When we open a blocked artery, we know we’ve improved blood flow through that artery and that relieves symptoms. But the bigger question is whether that translates into a reduction in clinical events such as heart attacks or death for patients over the long term,” Butala said. “We found no significant difference in the risk of death or heart attack between the two treatment groups” (CU Anschutz).
The analysis was limited to VA patients whose records could be linked (predominantly male veterans with higher baseline risks than the full trial cohort) and relied on administrative data for event ascertainment, though results aligned with adjudicated events from the original trial period. The authors concluded that the findings do not support a routine strategy of elective upfront PCI to reduce long-term death or MI in stable CAD.
Parallel long-term data from the ISCHEMIA trial extension (ISCHEMIA-EXTEND), also published in JAMA and presented at the same meeting, reinforced the pattern. Among 5,179 patients with stable coronary disease and moderate-to-severe ischemia, all-cause mortality at 11 years was 25.8% with an initial invasive strategy (angiography and revascularization when appropriate plus medical therapy) versus 26.9% with an initial conservative strategy (medical therapy first, with invasive care if needed), a nonsignificant difference (adjusted HR 0.97) (JAMA; MedPage Today). Cardiovascular mortality showed a numerical but nonsignificant trend favoring the invasive arm.
Researchers and editorialists emphasized that PCI and related procedures can still provide meaningful relief of angina (chest pain) and improve quality of life in symptomatic patients, and that they are lifesaving in acute coronary syndromes such as ongoing heart attacks. The results apply specifically to stable disease managed with contemporary optimal medical therapy, including lifestyle measures, and support shared decision-making that weighs symptom burden, procedural risks, and patient preferences rather than assuming prognostic benefit from opening arteries in stable settings (MedPage Today).
These extended analyses provide the longest available randomized evidence on the question, confirming earlier shorter-term results from COURAGE, ISCHEMIA, and related trials that optimal medical therapy is a safe and effective initial approach for most patients with stable coronary artery disease.
Sources
- scitechdaily.comhttps://scitechdaily.com/heart-stents-may-not-prevent-heart-attacks-or-early-death-landmark-study-finds/
- news.cuanschutz.eduhttps://news.cuanschutz.edu/news-stories/does-a-heart-stent-prevent-future-heart-attacks-in-stable-patients-25-year-follow-up-offers-new-insight
- medpagetoday.comhttps://www.medpagetoday.com/meetingcoverage/aha/123844
- jamanetwork.comhttps://jamanetwork.com/journals/jama/fullarticle/2856313
- healio.comhttps://www.healio.com/news/cardiology/20261108/no-clinical-benefit-for-pci-in-stable-coronary-artery-disease-longterm-data-show
- medscape.comhttps://www.medscape.com/viewarticle/even-after-25-year-follow-no-reduction-death-or-mi-found-2026a10016y9
- jamanetwork.comhttps://jamanetwork.com/journals/jama/fullarticle/2856395
Want to respond?
The Uncovered has no comment section by design — we don't host or moderate discussions. If you still want to read along or join in, you can do so over Nostr, an open protocol where your replies live on your own key instead of on our server. Install NostrComments for Chrome or Firefox and the discussion appears on top of this page. Works on desktop and on Firefox for Android.
Open source, no tracking, free.
More in Health
Researchers from Columbia University and the University of California, Berkeley, have shown that common microplastics spontaneously produce reactive oxygen species, including hydroxyl radicals, upon contact with water. The findings, published in Nature, challenge the long-held view that plastics are chemically inert and identify a potential mechanism for biological damage. More hydrophobic plastics generated higher levels of these reactive molecules, which correlated with damage to proteins and mouse red blood cells in lab tests.
21 Nov 2026
Two independent studies published in JAMA have linked elevated levels of the tau protein fragment eMTBR-tau in blood plasma to advanced chronic traumatic encephalopathy confirmed at autopsy. The findings from Boston University/Banner Health and Washington University researchers offer a potential path toward diagnosing the disease, currently only possible postmortem, in living individuals and enabling clinical trials. Researchers caution that the results are preliminary, based on small samples, and require larger validation studies before any clinical use.
20 Nov 2026
Researchers analyzing 212 plant-based products sold in the UK detected at least one mycotoxin in every sample, though concentrations remained below European Union guideline levels. The survey of meat alternatives and dairy substitutes, published in Food Control, highlights widespread natural fungal contaminants in grains, legumes and seeds used in these foods. Scientists note potential concerns about cumulative exposure from frequent consumption while stressing the findings do not indicate immediate unsafety.
20 Nov 2026